EDISON EQUITY RESEARCH: ANGLE
April 20 2016 - 10:05AM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
ANGLE: ADR
UPDATE - THIRD CLINICAL APPLICATION EMERGES
Angle has announced results from a metastatic breast cancer
research study carried out by its KOL partner University of
Southern California (USC) Norris Comprehensive Cancer Center.
Headline data potentially prove that circulating cancer cells
(CTCs) captured using Parsortix have the same biology compared to
invasive tissue biopsy and can be used to guide the treatment.
While this will have to be replicated in larger-scale trials, it
represents a potential third clinical application, in which
Parsortix can establish a new standard of care.
Angle is a pure-play specialist diagnostics company. The
proprietary Parsortix cell separation platform can be used for the
detection and harvesting of very rare cells from a blood sample,
including circulating tumor cells (CTCs). The resulting liquid
biopsy enables the analysis of these cells for precision cancer
care.
To view our full report, please click here
Click here to view all of Edison Investment
Research's published reports
Angle Plc Surrey (QX) (USOTC:ANPCY)
Historical Stock Chart
From Sep 2024 to Oct 2024
Angle Plc Surrey (QX) (USOTC:ANPCY)
Historical Stock Chart
From Oct 2023 to Oct 2024